Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros




Base de datos
Asunto de la revista
Intervalo de año de publicación
1.
Cell ; 185(13): 2338-2353.e18, 2022 06 23.
Artículo en Inglés | MEDLINE | ID: mdl-35662409

RESUMEN

Hijacking the cellular protein degradation system offers unique opportunities for drug discovery, as exemplified by proteolysis-targeting chimeras. Despite their great promise for medical chemistry, so far, it has not been possible to reprogram the bacterial degradation machinery to interfere with microbial infections. Here, we develop small-molecule degraders, so-called BacPROTACs, that bind to the substrate receptor of the ClpC:ClpP protease, priming neo-substrates for degradation. In addition to their targeting function, BacPROTACs activate ClpC, transforming the resting unfoldase into its functional state. The induced higher-order oligomer was visualized by cryo-EM analysis, providing a structural snapshot of activated ClpC unfolding a protein substrate. Finally, drug susceptibility and degradation assays performed in mycobacteria demonstrate in vivo activity of BacPROTACs, allowing selective targeting of endogenous proteins via fusion to an established degron. In addition to guiding antibiotic discovery, the BacPROTAC technology presents a versatile research tool enabling the inducible degradation of bacterial proteins.


Asunto(s)
Proteínas Bacterianas , Chaperonas Moleculares , Bacterias/metabolismo , Proteínas Bacterianas/metabolismo , Chaperonas Moleculares/metabolismo , Proteolisis
2.
J Med Chem ; 60(19): 8183-8191, 2017 10 12.
Artículo en Inglés | MEDLINE | ID: mdl-28933844

RESUMEN

Efforts to develop inhibitors, activators, and effectors of biological reactions using small molecule libraries are often hampered by interference compounds, artifacts, and false positives that permeate the pool of initial hits. Here, we report the discovery of a promising initial hit compound targeting the Fanconi anemia ubiquitin-conjugating enzyme Ube2T and describe its biophysical and biochemical characterization. Analysis of the co-crystal structure led to the identification of a contaminating zinc ion as solely responsible for the observed effects. Zinc binding to the active site cysteine induces a domain swap in Ube2T that leads to cyclic trimerization organized in an open-ended linear assembly. Our study serves as a cautionary tale for screening small molecule libraries and provides insights into the structural plasticity of ubiquitin-conjugating enzymes.


Asunto(s)
Enzimas Ubiquitina-Conjugadoras/química , Enzimas Ubiquitina-Conjugadoras/efectos de los fármacos , Compuestos de Zinc/química , Compuestos de Zinc/farmacología , Dominio Catalítico , Cristalografía por Rayos X , Cisteína , Ensayos Analíticos de Alto Rendimiento , Modelos Moleculares , Pliegue de Proteína , Estructura Secundaria de Proteína/efectos de los fármacos , Bibliotecas de Moléculas Pequeñas
3.
J Med Chem ; 60(9): 4093-4098, 2017 05 11.
Artículo en Inglés | MEDLINE | ID: mdl-28437106

RESUMEN

Ube2T is the E2 ubiquitin-conjugating enzyme of the Fanconi anemia DNA repair pathway and it is overexpressed in several cancers, representing an attractive target for the development of inhibitors. Despite the extensive efforts in targeting the ubiquitin system, very few E2 binders have currently been discovered. Herein we report the identification of a new allosteric pocket on Ube2T through a fragment screening using biophysical methods. Several fragments binding to this site inhibit ubiquitin conjugation in vitro.


Asunto(s)
Anemia de Fanconi/enzimología , Enzimas Ubiquitina-Conjugadoras/metabolismo , Regulación Alostérica , Humanos , Ubiquitinación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA